abrdn plc Has $37.68 Million Stake in argenx SE (NASDAQ:ARGX)

abrdn plc decreased its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 8.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 61,262 shares of the company's stock after selling 6,000 shares during the quarter. abrdn plc owned approximately 0.10% of argenx worth $37,676,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Cromwell Holdings LLC lifted its holdings in argenx by 73.3% during the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company's stock worth $85,000 after purchasing an additional 66 shares during the last quarter. GAMMA Investing LLC increased its position in argenx by 47.5% during the 3rd quarter. GAMMA Investing LLC now owns 174 shares of the company's stock worth $94,000 after buying an additional 56 shares during the period. Blue Trust Inc. lifted its holdings in shares of argenx by 413.9% during the third quarter. Blue Trust Inc. now owns 370 shares of the company's stock worth $201,000 after buying an additional 298 shares in the last quarter. Keudell Morrison Wealth Management acquired a new position in shares of argenx in the third quarter valued at about $207,000. Finally, SG Americas Securities LLC grew its stake in shares of argenx by 6.2% in the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company's stock valued at $220,000 after acquiring an additional 21 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Trading Down 1.7 %

Shares of NASDAQ ARGX traded down $11.33 during mid-day trading on Friday, hitting $646.64. 228,947 shares of the stock traded hands, compared to its average volume of 282,116. argenx SE has a twelve month low of $349.86 and a twelve month high of $678.21. The firm has a 50 day simple moving average of $637.11 and a two-hundred day simple moving average of $576.94.

Analyst Ratings Changes

ARGX has been the subject of a number of recent research reports. Evercore ISI boosted their price objective on shares of argenx from $675.00 to $706.00 and gave the company an "outperform" rating in a report on Thursday, November 21st. Wolfe Research upgraded argenx from a "peer perform" rating to an "outperform" rating and set a $697.00 price target for the company in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered argenx from a "hold" rating to a "sell" rating in a research note on Friday, January 17th. Oppenheimer reiterated an "outperform" rating and set a $675.00 target price (up from $646.00) on shares of argenx in a research report on Thursday, November 21st. Finally, Piper Sandler raised their price target on argenx from $620.00 to $725.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $658.39.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.